GSK

Milestones as listed on gsk.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on gsk.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on gsk.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on gsk.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for GSK (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.

Clinical trials 161 in our ClinicalTrials.gov registers · 17 in the EU register

Showing 10 of 161, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 3 registry names

Drugs in these trials 92 compounds

EU trials register (CTIS) 17 authorised or ongoing · 2 in Ireland

• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)2025-521627-78-00 · Phase III · Ongoing · site in Ireland
• The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.2025-524463-20-00 · Phase III · Ongoing · site in Ireland
• A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age2026-526925-17-00 · Phase III · Authorised
• A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age2026-526682-14-00 · Phase III · Ongoing
• A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.2025-522932-15-00 · Phase I · Ongoing
• A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy2025-523362-25-00 · Phase III · Authorised
• A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.2025-523361-25-00 · Phase III · Authorised
• A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).2025-523874-17-00 · Phase I/II · Authorised

Recent approvals

• ExdensurEMA · depemokimab · 12 Feb 2026

Medicine shortages 2 in the FDA list

• Fluticasone Propionate and Salmeterol Xinafoate Aerosol, MeteredUS (FDA) · resolved · updated 27 Jul 2026
• Maraviroc SolutionUS (FDA) · resolved · updated 20 Jan 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 21 of its medicines · 21 current

• Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyNICE TA1189 · Optimised · 26 Aug 2026
• Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsNICE TA1166 · Optimised · 17 Jun 2026
• Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaNICE TA1149 · Optimised · 30 Apr 2026
• Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myelomaNICE TA1133 · Optimised · 18 Feb 2026
• Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyNICE TA1129 · Optimised · 12 Feb 2026
• Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)NICE TA1123 · Terminated (no company submission) · 22 Jan 2026
• Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyNICE TA1117 · Optimised · 16 Dec 2025
• Cabotegravir for preventing HIV-1 in adults and young peopleNICE TA1106 · Optimised · 5 Nov 2025

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (GSK): founded 2000, headquarters London, website gsk.com. Wikidata Q212322 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here GlaxoSmithKline; ViiV Healthcare; Viiv Healthcare UK Limited; GlaxoSmithKline Biologicals; Glaxosmithkline Research & Development Limited; GSK PLC and 10 more. Spot a wrong match? Tell us.

From the annual reports GSK plc files with the US Securities and Exchange Commission (20-F, IFRS), in GBP as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 6 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to GSK plc as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.